We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Paradigm Genetics -- PDGM

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who started this subject10/23/2003 11:44:33 AM
From: nigel bates   of 101
Paradigm Genetics Receives U.S. Patent for Fungicide Target; Target Part of Fungal Pathway for Lysine Production

RESEARCH TRIANGLE PARK, N.C., Oct. 23 /PRNewswire-FirstCall/ -- Paradigm Genetics, Inc. (Nasdaq: PDGM - News), a biotechnology company, today announced that the company has been issued U.S. Patent No. 6,632,631, titled "Methods for the Identification of Inhibitors of Homocitrate Synthase as Antibiotics." The patent covers a gene target (homocitrate synthase) in the biosynthetic pathway by which fungi produce lysine, a nutrient necessary for fungi to thrive, as well as methods enabling the discovery of chemicals that inhibit enzymatic steps within the lysine pathway. Chemical compounds discovered by Paradigm's patented method may lead to the development of novel, less toxic fungicides or antifungals, which are highly sought after in the agricultural industry.

"The pathway used by fungi to make lysine is not present in humans and animals, and is very different from the lysine production pathway in plants," said Keith Davis, Ph.D., Vice President of Agricultural Research. "By focusing on fungal-specific pathways, such as lysine production, scientists can identify more selective and safer antifungal compounds. Our patented gene target is a critical first step in this powerful approach, and we expect that large agrochemical companies may be interested in licensing rights related to this patent for the development of effective, less toxic fungicidal products."

Paradigm used its patented TAG-KO® technology (U.S. Patent No. 6,562,624) to identify the target in the lysine pathway. Davis continued, "This discovery validates our TAG-KO® technology as a very compelling tool for the discovery and development of new antibiotic compounds such as new fungicides and human antifungals."
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext